Loading cancer entity…
Loading cancer entity…
Clinical trials
21 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07684287 | A Phase 2 Study of Sirolimus for Injection (Albumin-bound) in Patients With Progressive or Symptomatic Epithelioid Hemangioendothelioma | not yet recruiting | Phase 2 | 40 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07656909 | Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP | recruiting | Phase 2 / Phase 3 | 76 | Yi JiOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07104331 |
Data updated 23 days agoSource updated Aug 3, 2026source: clinicaltrials
| SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma |
| recruiting |
| Phase 2 |
| 41 |
| Sarcoma Alliance for Research through CollaborationOTHER |
| 1 |
| May 26, 2026 |
| clinicaltrials |
| NCT07477548 | A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies | not yet recruiting | Phase 2 | 67 | Yonsei UniversityOTHER | 0 | Mar 17, 2026 | clinicaltrials |